Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Vascular cognitive impairment, no dementia: diagnosis, prognosis, treatment, and prevention

https://doi.org/10.14412/2074-2711-2017-3-68-75

Full Text:

Abstract

The paper considers the concept of vascular cognitive impairment (CI), no dementia, their epidemiology, risk markers and pathological basis.
It describes in detail the neuropsychological characteristics of CI, relevant diagnostic criteria, and clinical and neuroimaging diagnostic techniques. In addition to stroke, cerebral small vessel disease, which is characterized in the article in a modern light, is shown to play an important role in the development of moderate vascular CI. The course, prognosis of vascular cognitive impairment, and their determinants are discussed. Approaches to the treatment of the disease, including nicergoline therapy, and preventive measures with emphasis on physical activity are presented.

About the Authors

A. A. Kulesh
Acad. E.A. Vagner Perm State Medical University, Ministry of Health of Russia
Russian Federation
26, Petropavlovskaya St., Perm, Perm Territory 614990


V. V. Shestakov
Acad. E.A. Vagner Perm State Medical University, Ministry of Health of Russia
Russian Federation
26, Petropavlovskaya St., Perm, Perm Territory 614990


References

1. Яхно НН, Захаров ВВ, Локшина АБ и др. Деменции. Руководство для врачей. Москва: МЕДпресс-информ; 2010. 272 c. [Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii. Rukovodstvo dlya vrachei [Dementia. A guide for physicians]. Moscow: MEDpressinform; 2010. 272 p.]

2. Fisher C. Dementia in cerebrovascular disease. New York: Grune and Stratton; 1968. P. 232-41.

3. Захаров ВВ. Эволюция когнитивного дефицита: легкие и умеренные когнитивные нарушения. Неврология, нейропсихиатрия, психосоматика. 2012;4(2):16-21. [Zakharov VV. Evolution of cognitive deficit: mild and moderate cognitive impairments. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(2): 16-21. (In Russ.)]. Doi: 10.14412/2074-2711-2012-376

4. Rockwood K, Wentzel C, Hachinski V, et al. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology. 2000 Jan 25;54(2):447-51.

5. Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Группа Ремедиум; 2014. 187 с. [Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive impairments]. Moscow: Gruppa Remedium; 2014. 187 p.]

6. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology. 1993 Feb; 43(2):250-60.

7. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999 Mar; 56(3):303-8.

8. Дамулин ИВ. Когнитивные расстройства сосудистого генеза: патогенетические, клинические и терапевтические аспекты. Нервные болезни. 2012;(4):14-20. [Damulin IV. Cognitive impairment of vascular origin: pathogenetic, clinical and therapeutic aspects. Nervnye bolezni. 2012;(4):14-20. (In Russ.)].

9. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association / american stroke association. Stroke. 2011 Sep; 42(9):2672-713. doi: 10.1161/STR.0b013e3182299496. Epub 2011 Jul 21.

10. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004 Sep; 256(3):183-94.

11. Захаров ВВ. Всероссийская программа изучения эпидемиологии когнитивных расстройств в пожилом возрасте («Прометей»). Неврологический журнал. 2006;11(2):27-32. [Zakharov VV. All-Russian program of study of cognitive disorders epidemiology in the elderly («Prometheus»). Nevrologicheskii zhurnal. 2006;11(2):27-32. (In Russ.)].

12. Захаров ВВ, Вознесенская ТГ. Нервнопсихические нарушения: диагностические тесты. Москва: МЕДпресс-информ; 2013. 320 с. [Zakharov VV, Voznesenskaya TG. Nervnopsikhicheskie narusheniya: diagnosticheskie testy [Neuro-psychiatric disorders: diagnostic tests]. Moscow: MEDpress-inform; 2013. 320 p.]

13. Sachdev PS, Brodaty H, Valenzuela MJ, et al. Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney Stroke Study. Dement Geriatr Cogn Disord. 2006;21(5-6):275-83. Epub 2006 Feb 10.

14. Tu QY, Yang X, Ding BR, et al. Epidemiological investigation of vascular cognitive impairment post ischemic stroke. Chinese Journal of Gerontology. 2011;31:3576-9.

15. Jacquin A, Binquet C, Rouaud O, et al. Post-stroke cognitive impairment: high prevalence and determining factors in a cohort of mild stroke. J Alzheimers Dis. 2014;40(4): 1029-38. doi: 10.3233/JAD-131580.

16. Кулеш АА, Шестаков ВВ. Постинсультные когнитивные нарушения и возможности терапии препаратом целлекс. Журнал неврологии и психиатрии им. C.C. Корсакова. 2016;(5):38-42. [Kulesh AA, Shestakov VV. Post-stroke cognitive impairment and the possibility of therapy with drug cellex. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016; (5):38-42. (In Russ.)].

17. Gorelick PB, Nyenhuis D. Understanding and treating vascular cognitive impairment. Continuum (Minneap Minn). 2013 Apr;19 (2 Dementia):425-37. doi: 10.1212/01.CON.0000429174.29601.de.

18. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):206-18. doi: 10.1097/WAD.0000000000000034.

19. Кулеш АА. Клинико-патогенетическая характеристика и прогнозирование исхода когнитивных нарушений при ишемическом инсульте в контексте взаимодействия процессов нейровоспаления, нейродегенерации, нейропротекции, макро- и микроструктурных церебральных факторов. Дисс. докт. мед. наук. Пермь; 2017. [Kulesh AA. Clinical and pathogenetic characteristics and prediction of outcome of cognitive impairment in ischemic stroke in the context of interaction of the processes of neuroinflammation, neurodegeneration, neuroprotection, macroand microstructural cerebral factors. Diss. doct. med. sci. Perm'; 2017.]

20. Dichgans M, Leys D. Vascular Cognitive Impairment. Circ Res. 2017 Feb 3;120(3):573-591. doi: 10.1161/CIRCRESAHA.116.308426.

21. Кулеш АА, Дробаха ВЕ, Шестаков ВВ, Некрасова ИВ, Куклина ЕМ. Нейровоспалительные, нейродегенеративные и структурные церебральные маркеры основных клинических вариантов постинсультных когнитивных нарушений в остром периоде ишемического инсульта. Вестник Российской академии медицинских наук. 2016;71(4):304-12. [Kulesh AA, Drobakha VE, Shestakov VV, Nekrasova IV, Kuklina EM. Neuroinflammatory, neurodegenerative and structural cerebral markers of the main clinical variants of post-stroke cognitive impairment in the acute period of ischemic stroke. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2016;71(4):304-12. (In Russ.)].

22. Rodriguez Garcia PL, Rodriguez Garcia D. Diagnosis of vascular cognitive impairment and its main categories. Neurologia. 2015 May;30(4): 223-39. doi: 10.1016/j.nrl.2011.12.014. Epub 2012 Jun 26.

23. Вахнина НВ, Никитина ЛЮ, Парфенов ВА, Яхно НН. Постинсультные когнитивные нарушения. Журнал неврологии и психиатрии им. C.C. Корсакова. 2008;22:16-21. [Vakhnina NV, Nikitina LYu, Parfenov VA, Yakhno NN. Post-stroke cognitive impairment. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2008;22:16-21. (In Russ.)].

24. Looi LC, Sachdev P. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology. 1999 Sep 11;53(4):670-8.

25. Sachdev PS, Chen Х, Brodaty H, et al. The determinants and longitudinal course of post – stroke mild cognitive impairment. J Int Neuropsychol Soc. 2009 Nov;15(6):915-23. doi: 10.1017/S1355617709990579.

26. Godefroy O. The behavioral and cognitive neurology of stroke. 2nd ed. Cambridge University Press; 2013. 442 p.

27. Stuss DT, Alexander MP. Executive functions and the frontal lobes: A conceptual view. Psychol Res. 2000;63(3-4):289-98.

28. Парфенов ВА. Постинсультная депрессия: распространенность, патогенез, диагностика и лечение. Неврология, нейропсихиатрия, психосоматика. 2012;4:84-8. [Parfenov VA. Poststroke depression: prevalence, pathogenesis, diagnosis, and treatment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(4):84-8. (In Russ.)]. doi: 10.14412/2074-2711-2012-42

29. Парфенов ВА. Ранняя диагностика и лечение болезни Альцгеймера. Медицинский совет. 2015;(5):28-33. [Parfenov VA. Early diagnosis and treatment of Alzheimer's disease. Meditsinskii sovet. 2015;(5):28-33. (In Russ.)].

30. Неверовский ДВ, Случевская СФ, Парфенов ВА. Дифференциальный диагноз дисциркуляторной энцефалопатии в амбулаторной практике. Неврология, нейропсихиатрия, психосоматика. 2013;5(2):38–42. [Neverovskii DV, Sluchevskaya SF, Parfenov VA. Differential diagnosis of dyscirculatory encephalopathy in outpatient practice. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(2):38–42. (In Russ.)]. doi: 10.14412/2074-2711-2013-2411

31. Парфенов ВА, Неверовский ДВ. Ведение пациентов с дисциркуляторной энцефалопатией в амбулаторной практике. Неврология, нейропсихиатрия, психосоматика. 2015;7(1):37-42. [Parfenov VA, Neverovsky DV. Outpatient management of patients with dyscirculatory encephalopathy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2015;(1):37-42. (In Russ.)]. doi: http://dx.doi.org/10.14412/2074-2711-2015-1-37-42

32. Toglia JK, Fitzgerald A, O’Dell MW, et al. The Mini-Mental State Examination and Montreal Cognitive Assessment in persons with mild subacute stroke: relationship to functional outcome. Arch Phys Med Rehabil. 2011 May;92 (5):792-8. doi: 10.1016/j.apmr.2010.12.034.

33. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9.

34. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006 Sep;37(9):2220-41. Epub 2006 Aug 17.

35. Лурия АР. Высшие корковые функции человека и их нарушения при локальных поражениях мозга. Москва: Издательство МГУ; 1969. 504 с. [Luriya AR. Vysshie korkovye funktsii cheloveka i ikh narusheniya pri lokal'nykh porazheniyakh mozga [Higher cortical functions in man and their disturbances in local brain lesions]. Moscow: Izdatel'stvo MGU; 1969. 504 p.]

36. Jellinger KA. Morphologic diagnosis of «vascular dementia»: a critical update. J Neurol Sci. 2008 Jul 15;270(1-2):1-12. doi: 10.1016/j.jns.2008.03.006. Epub 2008 May 2.

37. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010 Jul;9(7):689-701. doi: 10.1016/S1474-4422(10)70104-6.

38. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013 May;12(5):483-97. doi: 10.1016/S1474-4422(13)70060-7.

39. Staals J, Booth T, Morris Z, et al. Total MRI load of cerebral small vessel disease and cognitive ability in older people. Neurobiol Aging. 2015 Oct;36(10):2806-11. doi: 10.1016/j.neurobiolaging.2015.06.024. Epub 2015 Jun 26.

40. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta – analysis. BMJ. 2010 Jul 26; 341:c3666. doi: 10.1136/bmj.c3666..

41. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013 Aug;12 (8):822-38. doi: 10.1016/S1474-4422(13)70124-8.

42. de Lange AG, Brathen AC, Grydeland H, et al. White matter integrity as a marker for cognitive plasticity in aging. Neurobiol Aging. 2016 Nov;47:74-82. doi: 10.1016/j.neurobiolaging.2016.07.007. Epub 2016 Jul 15.

43. Zhou Y, Qun Xu, Qin KD, et al. A primary study of diffusion tensor imaging – based histogram analysis in vascular cognitive impairment with no dementia. Clin Neurol Neurosurg. 2011 Feb;113(2):92-7. doi: 10.1016/j.clineuro. 2010.09.007. Epub 2010 Oct 13.

44. Barba R, Martinez-Espinosa S, RodriguezGarcia E, et al. Poststroke dementia: clinical features and risk factors. Stroke. 2000 Jul;31 (7):1494-501.

45. Nakano Y, Deguchi K, Yamashita T, et al. High Incidence of Dementia Conversion than Stroke Recurrence in Poststroke Patients of Late Elder Society. J Stroke Cerebrovasc Dis. 2015 Jul;24(7):1621-8. doi: 10.1016/j.jstrokecerebrovasdis.2015.03.037. Epub 2015 Apr 22.

46. Кулеш AA, Дробаха BE, Куклина EM, Шестаков BB. Когнитивная траектория пациентов в восстановительном периоде ишемического инсульта: роль нейровоспаления и структурных церебральных факторов. Казанский медицинский журнал. 2017;(4):513-8. [Kulesh AA, Drobakha BE, Kuklina EM, Shestakov BB. The cognitive trajectory of patients in rehabilitation period of ischemic stroke: the role of neuroinflammation and cerebral structural factors. Kazanskii meditsinskii zhurnal. 2017;(4):513-8. (In Russ.)].

47. Roman GC, Erkinjuntti T, Wallin L. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002 Nov;1(7):426-36.

48. Парфенов ВА, Соловьева ЭЮ, Антоненко ЛМ и др. Лечение комбинированных когнитивных и эмоциональных нарушений у больных молодого и среднего возраста. Неврология, нейропсихиатрия, психосоматика. 2016;8(2):17-23. [Parfenov VA, Solov'eva EYu, Antonenko LM, et al. Treatment for mixed cognitive impairments and emotional disorders in young and middle-aged patients. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(2):17-23. (In Russ.)]. doi: 10.14412/2074-2711-2016-2-17-23

49. Парфенов ВА. Диагноз и лечение хронического цереброваскулярного заболевания, применение пентоксифиллина. Неврология, нейропсихиатрия, психосоматика. 2016;8(3):4-9. [Parfenov VA. Diagnosis and treatment of chronic cerebrovascular disease, use of pentoxifylline. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(3):4-9. (In Russ.)]. doi: 10.14412/2074-2711-2016-3-4-9

50. Saletu B, Garg A, Shoeb A. Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders. Biomed Res Int. 2014;2014:610103. doi: 10.1155/2014/610103. Epub 2014 Aug 28.

51. Winblad B, Fioravanti M, Dolezal T, et al. Therapeutic use of nicergoline. Clin Drug Investig. 2008;28(9):533-52.

52. Caraci F, Chisari M, Frasca G, et al. Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against β-amyloid toxicity. Brain Res. 2005 Jun 14;1047(1):30-7.

53. Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev. 2001;(4):CD003159.

54. Fioravanti М, Nakashima М, Xu J, et al. A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline. BMJ Open. 2014 Jul 30;4(7):e005090. doi: 10.1136/bmjopen-2014-005090.

55. Парфенов ВА, Старчина ЮА. Когнитивные расстройства и их лечение при артериальной гипертонии. Нервные болезни. 2015; (1):16-22. [Parfenov VA, Starchina YuA. Cognitive disorders and their treatment with arterial hypertension. Nervnye bolezni. 2015;(1): 16-22. (In Russ.)].

56. Парфенов ВА, Вербицкая СВ. Вторичная профилактика ишемического инсульта и когнитивных нарушений. Медицинский совет. 2016;(11):18-24. [Parfenov VA, Verbitskaya SV. Secondary prevention of ischemic stroke and cognitive impairment. Meditsinskii sovet. 2016;(11):18-24. (In Russ.)].

57. Andrieu S, Coley N, Lovestone S, et al. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol. 2015 Sep;14(9):926-44. doi: 10.1016/S1474-4422(15)00153-2. Epub 2015 Jul 23.

58. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12.

59. Groot C, Hooghiemstra AM, Raijmakers PG, et al. The effect of physical activity on cognitive function in patients with dementia: A metaanalysis of randomized control trials. Ageing Res Rev. 2016 Jan;25:13-23. doi: 10.1016/j.arr.2015.11.005. Epub 2015 Nov 28.


For citation:


Kulesh A.A., Shestakov V.V. Vascular cognitive impairment, no dementia: diagnosis, prognosis, treatment, and prevention. Neurology, Neuropsychiatry, Psychosomatics. 2017;9(3):68-75. (In Russ.) https://doi.org/10.14412/2074-2711-2017-3-68-75

Views: 331


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)